Reprinting FDAMA Approach: Waxman Urges FDA Review Of Off-Label Articles
Executive Summary
Rep. Henry Waxman, D-Calif., is pushing FDA to require companies to submit reprints of journal articles on off-label use before providing them to practitioners, should the agency go forward with guidance permitting off-label promotion
You may also be interested in...
Waxman Asks FDA To Explain How Its Regulatory Priorities Aid Public Health
Rep. Henry Waxman, D-Calif., is challenging FDA's priorities for writing rules and guidances, saying the agency appears to be more interested in loosening marketing restrictions and reducing product liability for drug and device makers than in protecting public health
Waxman Asks FDA To Explain How Its Regulatory Priorities Aid Public Health
Rep. Henry Waxman, D-Calif., is challenging FDA's priorities for writing rules and guidances, saying the agency appears to be more interested in loosening marketing restrictions and reducing product liability for drug and device makers than in protecting public health
DoJ, Congress Want Ad Oversight: FDA Sounds Ready To Respond
The Department of Justice's level of interest in drug industry promotional issues seems to be increasing, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams told the Food & Drug Law Institute advertising and promotion conference Sept. 8